Summary
The product CYPILOS 250 mg/ml, manufactured by Driada Medical, underwent independent laboratory testing to verify its composition and dosage accuracy. The analysis, conducted by Janoshik Analytical, identified the active ingredient as testosterone cypionate, with a measured concentration of 230.65 mg/ml, which is 7.74% below the labeled claim of 250 mg/ml. Despite this variance, the dosage falls within acceptable industry standards.
Testing commenced on 13 December 2021, with the sample received on 14 December 2021, and the analysis concluded on 16 December 2021. The product was submitted and funded by Driada Medical, necessitating careful interpretation of the results.
Detailed Report
Product Overview
- Manufacturer: Driada Medical
- Product Name: CYPILOS 250 mg/ml
- Active Ingredient: Testosterone Cypionate
- Batch Number: 065517
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #15091
- Testing Ordered: 13 December 2021
- Sample Received: 14 December 2021
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Driada Medical
- Analysis Paid For By: Driada Medical
Testing Results
- Specification: 250 mg/ml (as stated on the label)
- Measured Concentration: 230.65 mg/ml
- Accuracy: 92.26% (7.74% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/15091_AE8GAVNBSFMD
- Originally Published: https://thinksteroids.com/community/posts/2988722/
Evaluation of Manufacturer-Funded Testing
The testing was both submitted and funded by the manufacturer, Driada Medical, which requires critical evaluation of potential biases. The analysis by Janoshik Analytical, a reputable independent lab, provides confidence in the results despite the variance from the label claim.
Conclusion
The laboratory testing of CYPILOS 250 mg/ml confirms the presence of the active ingredient, testosterone cypionate, at a concentration slightly below the labeled claim. This variance highlights the importance of independent verification in ensuring product quality and supporting harm reduction in the anabolic steroid market.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside independent results. Readers are encouraged to interpret this information responsibly.
